Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain
Autor: | M R Kruis, M H van der Vegt, J. T. Wegener, J. H. Vranken, D Troost |
---|---|
Přispěvatelé: | ACS - Amsterdam Cardiovascular Sciences, Other Research, Anesthesiology, ANS - Amsterdam Neuroscience, Pathology |
Jazyk: | angličtina |
Rok vydání: | 2005 |
Předmět: |
medicine.medical_specialty
Pain Neoplasms medicine Humans Ketamine Bupivacaine Analgesics business.industry Chronic pain Middle Aged medicine.disease Surgery Clonidine Anesthesiology and Pain Medicine Peripheral neuropathy Spinal Cord Neurology Postmortem Changes Anesthesia Morphine Female Intractable pain Neurology (clinical) Cancer pain business medicine.drug |
Zdroj: | Pain, 117(1-2), 231-235. Elsevier |
ISSN: | 0304-3959 |
DOI: | 10.1016/j.pain.2005.06.014 |
Popis: | Questions have been raised about the potential neurotoxicity of the neuraxial use of ketamine although ketamine and its active enantiomer S(+)-ketamine have been used intrathecally and epidurally (caudally) for the management of perioperative pain and in a variety of chronic pain syndromes. Clinical experience following neuraxial administration of S(+)-ketamine has been documented without reference to local central nervous system toxicity following this approach. In addition, there are no preclinical safety data regarding stability, compatibility, and neurotoxicity on intrathecal use of single S(+)-ketamine or combinations of S(+)-ketamine, morphine, bupivacaine, and clonidine. In the present case, the continuous intrathecal administration of S(+)-ketamine, in combination with morphine, bupivacaine, and clonidine resulted in adequate pain relief in a patient suffering from intractable neuropathic cancer pain: However, postmortem observation of the spinal cord and nerve roots revealed severe histological abnormalities including central chromatolysis, nerve cell shrinkage, neuronophagia, microglial upregulation, and gliosis. Based on our results, neuraxial administration of S (+)-ketamine cannot be recommended for clinical practise before a systematic study of toxicology of neuraxial S(+)-ketamine in animals or humans has been performed. (c) 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved |
Databáze: | OpenAIRE |
Externí odkaz: |